High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study

PLoS One. 2014 Nov 13;9(11):e112578. doi: 10.1371/journal.pone.0112578. eCollection 2014.

Abstract

Background: In cystic fibrosis, highly variable glucose tolerance is suspected. However, no study provided within-patient coefficients of variation. The main objective of this short report was to evaluate within-patient variability of oral glucose tolerance.

Methods: In total, 4,643 standardized oral glucose tolerance tests of 1,128 cystic fibrosis patients (median age at first test: 15.5 [11.5; 21.5] years, 48.8% females) were studied. Patients included were clinically stable, non-pregnant, and had at least two oral glucose tolerance tests, with no prior lung transplantation or systemic steroid therapy. Transition frequency from any one test to the subsequent test was analyzed and within-patient coefficients of variation were calculated for fasting and two hour blood glucose values. All statistical analysis was implemented with SAS 9.4.

Results: A diabetic glucose tolerance was confirmed in 41.2% by the subsequent test. A regression to normal glucose tolerance at the subsequent test was observed in 21.7% and to impaired fasting glucose, impaired glucose tolerance or both in 15.2%, 12.0% or 9.9%. The average within-patient coefficient of variation for fasting blood glucose was 11.1% and for two hour blood glucose 25.3%.

Conclusion: In the cystic fibrosis patients studied, a highly variable glucose tolerance was observed. Compared to the general population, variability of two hour blood glucose was 1.5 to 1.8-fold higher.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Analysis of Variance
  • Blood Glucose / metabolism*
  • Child
  • Cystic Fibrosis / blood*
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / physiopathology
  • Diabetes Complications
  • Diabetes Mellitus / blood*
  • Diabetes Mellitus / physiopathology
  • Fasting
  • Female
  • Glucose Intolerance / blood*
  • Glucose Intolerance / complications
  • Glucose Intolerance / physiopathology
  • Glucose Tolerance Test
  • Humans
  • Male
  • Young Adult

Substances

  • Blood Glucose

Grants and funding

The study was funded by the German and French CF associations (Mukoviszidose e.V. and its regional group Saarland-Pfalz, Vaincre de la Mucoviszidose), and by Novo Nordisk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.